Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma

Van Cutsem, Eric; A. Tempero, Margaret; Sigal, Darren; Oh, Do‐Youn; Fazio, Nicola; Macarulla, Teresa; Hitre, Erika; Hammel, Pascal; Hendifar, Andrew; E. Bates, Susan; Li, Chung‐Pin; R. Hingorani, Sunil; de la Fouchardière, Christelle; Kasi, Anup; Heinemann, Volker; Maraveyas, Anthony; Bahary, Nathan; Layos, Laura; Sahai, Vaibhav; Zheng, Lei; Lacy, Jill; Oh Park, Joon; Portales, Fabienne; E. Oberstein, Paul; Wu, Wilson; Chondros, Dimitrios; J. Bullock, Andrea; behalf of the HALO 109-301 Investigators, on

doi:10.1200/jco.20.00590

Public

Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma

Published in Journal of Clinical Oncology • Jul 24, 2020

Authors:

Eric Van Cutsem

Margaret A. Tempero

Darren Sigal

Abstract

PURPOSE To evaluate the efficacy and safety of pegvorhyaluronidase alfa (PEGPH20) plus nab-paclitaxel/gemcitabine (AG) in patients with hyaluronan-high metastatic pancreatic ductal adenocarcinoma (PDA). PATIENTS AND METHODS HALO 109-301 was a phase III, randomized, double-blind, placebo-controlled s...

Subject

Medicine

Gemcitabine

Placebo

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!